Data Insights

LM-302 by Bristol-Myers Squibb for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...

Data Insights

LM-302 by Bristol-Myers Squibb for Esophageal Cancer: Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...

Data Insights

LM-302 by Bristol-Myers Squibb for Gastric Cancer: Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Data Insights

LM-302 by Bristol-Myers Squibb for Pancreatic Cancer: Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Data Insights

LM-302 by Bristol-Myers Squibb for Colorectal Cancer: Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...

Data Insights

LM-302 by Bristol-Myers Squibb for Ovarian Cancer: Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...

Data Insights

LM-302 by Bristol-Myers Squibb for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - LM-302 in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

LM-302 by Bristol-Myers Squibb for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - LM-302 in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

LM-302 by Bristol-Myers Squibb for Esophageal Cancer: Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LM-302 in Esophageal Cancer

Data Insights

LM-302 by Bristol-Myers Squibb for Gastric Cancer: Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LM-302 in Gastric Cancer

Data Insights

LM-302 by Bristol-Myers Squibb for Pancreatic Cancer: Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LM-302 in Pancreatic Cancer

Data Insights

LM-302 by Bristol-Myers Squibb for Colorectal Cancer: Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LM-302 in Colorectal Cancer

Data Insights

LM-302 by Bristol-Myers Squibb for Ovarian Cancer: Likelihood of Approval

LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LM-302 in Ovarian Cancer